search
Back to results

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Primary Purpose

Short Bowel Syndrome, Short Gut Syndrome, SBS

Status
Withdrawn
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Sponsored by
Marathon Pharmaceuticals, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Short Bowel Syndrome focused on measuring Short Bowel Syndrome, SBS, Chronic Diarrhea, Short Bowel, Short Gut, Short Gut Syndrome, Anti-Diarrheal, Opium Tincture, loperamide, diphenoxylate, ileostomies, tincture of opium, DTO, codeine, morphine, opiate

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Be male or female adults, 18 years of age or older
  • Have SBS that is inadequately controlled on current antidiarrheal medication (e.g., loperamide or diphenoxylate), including subjects with ileostomies
  • Must have been deemed a completer of study protocol MP-101-CL-001.
  • Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months of natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy)
  • Females of childbearing potential must agree to use 1 of the following acceptable birth control methods:

    • Surgically sterile (hysterectomy or bilateral oophorectomy)
    • Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation)
    • Intrauterine device (IUD) in place for at least 3 months
    • Abstinence (not having sexual intercourse)
    • Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion
    • Stable hormonal contraceptive for at least 3 months prior to study and through study completion
    • Vasectomized partner
  • Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at Visit 1.
  • Be able to understand and provide signed informed consent

Exclusion Criteria:

  • Have any history of or active neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic disease that is considered clinically significant, is not currently controlled by medication, and is stable as deemed by the Investigator
  • Are currently taking antibiotics for bacterial overgrowth
  • Have known or suspected pregnancy, planned pregnancy, or lactation
  • Have a planned surgery during the course of the study
  • Have a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk

Sites / Locations

  • Northwestern University Feinberg School of Medicine
  • Indiana University
  • Cleveland Clinic
  • Regional Infectious Disease Infusion Center
  • Vanderbilt Center for Human Nutrition

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

All Subjects

Arm Description

Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

Outcomes

Primary Outcome Measures

Number of Participants with Adverse Events

Secondary Outcome Measures

Full Information

First Posted
September 19, 2014
Last Updated
February 16, 2015
Sponsor
Marathon Pharmaceuticals, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT02246816
Brief Title
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
Official Title
A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Withdrawn
Why Stopped
Transfer of IND to different marketing authorization representative.
Study Start Date
February 2015 (undefined)
Primary Completion Date
February 2018 (Anticipated)
Study Completion Date
February 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Marathon Pharmaceuticals, LLC

4. Oversight

5. Study Description

Brief Summary
MP-101 will be evaluated in this study to see if it is safe and tolerable.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Gut
Keywords
Short Bowel Syndrome, SBS, Chronic Diarrhea, Short Bowel, Short Gut, Short Gut Syndrome, Anti-Diarrheal, Opium Tincture, loperamide, diphenoxylate, ileostomies, tincture of opium, DTO, codeine, morphine, opiate

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
All Subjects
Arm Type
Experimental
Arm Description
Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Intervention Type
Drug
Intervention Name(s)
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Intervention Description
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Primary Outcome Measure Information:
Title
Number of Participants with Adverse Events
Time Frame
Up to 120 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be male or female adults, 18 years of age or older Have SBS that is inadequately controlled on current antidiarrheal medication (e.g., loperamide or diphenoxylate), including subjects with ileostomies Must have been deemed a completer of study protocol MP-101-CL-001. Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months of natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy) Females of childbearing potential must agree to use 1 of the following acceptable birth control methods: Surgically sterile (hysterectomy or bilateral oophorectomy) Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation) Intrauterine device (IUD) in place for at least 3 months Abstinence (not having sexual intercourse) Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion Stable hormonal contraceptive for at least 3 months prior to study and through study completion Vasectomized partner Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at Visit 1. Be able to understand and provide signed informed consent Exclusion Criteria: Have any history of or active neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic disease that is considered clinically significant, is not currently controlled by medication, and is stable as deemed by the Investigator Are currently taking antibiotics for bacterial overgrowth Have known or suspected pregnancy, planned pregnancy, or lactation Have a planned surgery during the course of the study Have a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk
Facility Information:
Facility Name
Northwestern University Feinberg School of Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Indiana University
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Regional Infectious Disease Infusion Center
City
Lima
State/Province
Ohio
ZIP/Postal Code
45801
Country
United States
Facility Name
Vanderbilt Center for Human Nutrition
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212-1150
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

We'll reach out to this number within 24 hrs